Rocuronium Bromide Injection 10 mg per 5 mL Vial 10/Box

Premium Non-Depolarizing Muscle Relaxant for Rapid Sequence Intubation, Anesthesia, and Critical Care Emergencies

The Professional Standard in Non-Depolarizing Neuromuscular Blockade

Rocuronium Bromide Injection 10 mg per 5 mL Vial by Be Pharmaceuticals is a hospital-grade, fast-acting, non-depolarizing neuromuscular blocking agent. Rocuronium is widely used for rapid sequence intubation (RSI), facilitating endotracheal intubation, mechanical ventilation, and skeletal muscle relaxation during surgical procedures. Trusted by anesthesiologists, ER teams, and critical care specialists worldwide, Rocuronium delivers rapid onset, titratable duration, and reliable paralysis when it matters most.

Uses

Rocuronium Bromide Injection is indicated for:

• Rapid sequence induction/intubation (RSI): Facilitates endotracheal intubation, including emergent airway management in the operating room, ICU, or emergency department.
• Skeletal muscle relaxation during surgery: As part of general anesthesia in adults and pediatric patients.
• Facilitation of mechanical ventilation: Especially in critically ill or ventilator-dependent patients.
• Adjunct in electroconvulsive therapy (if paralysis required)
• Short procedures requiring muscle paralysis (by expert clinicians)

Order Rocuronium Bromide Injection 10 mg/5 mL Vial 10/Box by Be Pharmaceuticals

Ensure your airway, anesthesia, and emergency teams are ready for any scenario with FDA-approved, high-purity rocuronium—essential for surgery, critical care, and emergency intubation.

NDC: 71839-0141-10 | UPC: 371839141104 Prescription required. For use by licensed medical professionals only.

Uses and Applications

Rocuronium Bromide Injection is indicated for:

• Rapid sequence induction/intubation (RSI): Facilitates endotracheal intubation, including emergent airway management in the operating room, ICU, or emergency department.
• Skeletal muscle relaxation during surgery: As part of general anesthesia in adults and pediatric patients.
• Facilitation of mechanical ventilation: Especially in critically ill or ventilator-dependent patients.
• Adjunct in electroconvulsive therapy (if paralysis required)
• Short procedures requiring muscle paralysis (by expert clinicians)

Suitable for adult and pediatric (infant to adolescent) hospital and anesthesia practice.

Product Specifications

• Active Ingredient: Rocuronium Bromide 10 mg per 5 mL (2 mg/mL)
• Dosage Form: Clear, colorless, sterile, preservative-free solution for intravenous injection
• Packaging: 5 mL single-use vials in a box of 10 vials (total: 100 mg)
• Route: IV push or IV infusion
• Manufacturer: Be Pharmaceuticals
• NDC: 71839-0141-10
• UPC: 371839141104
• Latex-free and suitable for all hospital settings
• Storage: Refrigerate (2°–8°C/36°–46°F); may be stored at room temp for up to 60 days

How to Use

1. Review patient allergies, medical status, and monitoring readiness prior to administration.
2. Visually inspect vial for clarity and particulate matter prior to use. Do not use if discolored or cloudy.
3. Aspirate entire vial contents using a sterile syringe.
4. Administer IV push or infusion as directed by dosing protocols. Always ensure airway management equipment and skilled providers are present.
5. Continuous neuromuscular monitoring is recommended (e.g., train-of-four monitoring during prolonged use).
6. Do NOT mix with other drugs in same syringe. Use dedicated IV line where possible.

ONLY to be administered by qualified medical professionals in controlled, monitored settings.

Dosage and Administration

• Adults (Intubation, RSI):

  • Initial RSI dose: 0.6–1.2 mg/kg IV push. Typical 70 kg adult: 42–84 mg or 21–42 mL (multiple vials per patient dose).
  • Onset: 1–2 minutes; duration: 30–70 minutes.

• Maintenance of paralysis:

  • 0.1–0.2 mg/kg as needed, or continuous infusion at 0.01–0.012 mg/kg/min.

• Pediatric dosing:

  • Similar doses per actual body weight; consult pediatric guidelines.

• Renal/hepatic impairment:

  • Use lowest effective dose and monitor for prolonged paralysis.

Dosage individualized by weight, desired duration, and patient factors. Monitor neuromuscular function and vital signs throughout.

Drug Interactions

• Other neuromuscular blockers: Additive/paralytic effect (e.g., vecuronium, pancuronium)
• Aminoglycoside antibiotics, tetracyclines, polymyxins: Enhanced or prolonged blockade
• Volatile/inhaled anesthetics (isoflurane, enflurane, sevoflurane, desflurane): Potentiation of rocuronium effect
• Magnesium, lithium, calcium channel blockers: Increased neuromuscular blockade
• Cholinesterase inhibitors (neostigmine, pyridostigmine): Reversal of effect
• Phenytoin, carbamazepine: May reduce duration of action

Always inform anesthesia team of all co-administered medications.

Side Effects

Common Side Effects

• Transient hypotension or hypertension
• Transient tachycardia
• Injection site discomfort or irritation
• Mild skin flushing

Serious/Rare Side Effects

• Prolonged paralysis or residual muscle weakness
• Bronchospasm, laryngospasm, or anaphylaxis (rare)
• Arrhythmias or asystole (rare, mostly with overdose)
• Injection site extravasation and tissue necrosis
• Hypersensitivity reactions

Monitor ventilatory and cardiovascular function continuously. Full recovery of muscle strength is required before extubation.

Warnings and Precautions

• For hospital/professional use only—NOT for home or self-administration.
• Airway equipment and skilled providers must be available (intubation and ventilatory support required).
• Respiratory paralysis is predictable and must be managed with mechanical ventilation.
• Use with caution in myasthenia gravis, neuromuscular disease, electrolyte imbalance, or renal/hepatic dysfunction.
• Complete reversal with appropriate agents (sugammadex, neostigmine/atropine) required prior to emergence.
• NOT for use without close monitoring of tachyphylaxis, cumulative dose, and neuromuscular recovery.
• Pregnancy and pediatric use: Only as directed by experienced clinicians.